SEC set to review Covaxin trial data for use in children

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3uONY0y
via IFTTT

0 comments:

Post a Comment